Towards an understanding of the post-treatment and mechanistic aspects of tominersen
GENERATION HD1 (NCT03761849) was a randomised, multicentre, double-blind, Phase III, placebo-controlled trial designed to evaluate the safety and efficacy of tominersen in adults with manifest Huntington’s disease. In March 2021, dosing was stopped in GENERATION HD1 following a recommendation from the independent data monitoring committee. This presentation outlines data from the GENERATION HD1 post-treatment analysis which further our mechanistic understanding of tominersen and support next steps for the tominersen programme.